Abstract: There are provided a radical polymerizable composition having a low viscosity suitable for coating and a cured product and a plastic lens each obtained by curing the composition, the cured product having a high refractive index, good adhesiveness to a plastic film substrate, and good adhesiveness kept even under high-temperature and high-humidity conditions. The radical polymerizable composition includes phenylbenzyl (meth)acrylate (A), an epoxy (meth)acrylate (X) having an aromatic ring in its molecular structure, and a radical polymerization initiator (Y) as essential components.

Abstract: Disclosed herein are broad molecular weight distribution olefin polymers having densities in the 0.895 to 0.930 g/cm3 range, and with improved impact and tear resistance. These polymers can have a ratio of Mw/Mn in the 8 to 35 range, a high load melt index in the 4 to 50 range, less than about 0.008 LCB per 1000 total carbon atoms, and a reverse comonomer distribution.

Abstract: In one aspect, the invention relates to hydrolysis-resistant silicone compounds. In particular, disclosed are sterically hindered hydrolysis-resistant silicone compounds and improved purity hydrolysis-resistant silicone compounds. Also disclosed are processes for making hydrolysis-resistant silicone compounds; the products of the disclosed processes; compositions and polymers comprising the disclosed compounds and products of the disclosed processes; and ophthalmic lenses, for example contact lenses, intraocular lenses, artificial cornea, and spectacle lenses, comprising the disclosed compositions, disclosed polymers, disclosed compounds, and products of the disclosed processes. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: There is provided a production method of poly(phenylene ether ether ketone). The production method makes a cyclic poly(phenylene ether ether ketone) composition subjected to thermal ring-opening polymerization in the presence of a metal alkoxide and/or a metal phenoxide. The cyclic poly(phenylene ether ether ketone) composition includes 60% by weight or more of cyclic poly(phenylene ether ether ketone) and has a melting point of 270° C. or lower.

Abstract: A polymeric material includes phenyl moieties, ketone moieties and ether moieties in the polymeric backbone of said polymeric material, wherein the difference between the nucleation temperature (Tn) and the glass transition temperature (Tg) of said polymeric material is greater than 23° C.

Abstract: A copolycarbonate which is derived from a renewable resource and excellent in heat resistance, flowability and transparency and prevented from undergoing a dimensional change by water absorption and coloring during molding as well as a transparent molded article obtained therefrom. The copolycarbonate comprises predetermined amounts of a unit (A) constituted of an ether diol residue represented by the following formula (1), a unit (B) constituted of a bisphenol residue represented by the following formula (2), and a unit (C) constituted of another diol residue, wherein the ratio of terminal groups falls within the ranges of the following expressions (i) and (ii). (i) 0.001<total number of hydroxyl groups derived from the unit (A) and the unit (C)/total number of all terminal groups<0.3 (ii) 0.02<number of phenolic hydroxyl groups derived from the unit (B)/total number of all terminal groups<0.

Abstract: A method for producing a polyarylene sulfide resin, comprising: producing a slurry (I) containing a solid alkali metal sulfide by allowing a hydrous alkali metal sulfide, or a hydrous alkali metal hydrosulfide and an alkali metal hydroxide, and an aliphatic cyclic compound (c1) that can be ring-opened by hydrolysis to react with each other while conducting dehydration in the presence of a non-hydrolyzable organic solvent; adding an aprotic polar organic solvent after the production of the slurry (I) and distilling off water to conduct dehydration; and conducting polymerization by allowing a polyhaloaromatic compound (a), an alkali metal hydrosulfide (b), and an alkali metal salt (c2) of a hydrolysate of the compound (c1) to react with each other in the slurry (I) in a state where the amount of water existing in the reaction system is 0.02 moles or less relative to 1 mole of the aprotic polar organic solvent.

Abstract: Using a biopanning method, a heat-stable antibody-displayed phage is acquired. More particularly, first, an antibody-displayed phage library aqueous solution containing plural types of antibody-displayed phages is supplied to a support comprising a polypeptide on the surface thereof, so as to bind the plural types of the antibody-displayed phages to the polypeptide specifically. Next, the support is heated to the temperature of not less than 37 degrees Celsius and not more than 70 degrees Celsius, so as to release a portion of the antibody-displayed phages from the support and so as to leave the other antibody-displayed phages on the support selectively. Finally, the other antibody-displayed phages which has been left on the support selectively in the previous step is collected to obtain the heat-stable antibody-displayed phage.

Abstract: The present invention relates to ?-PNA monomers according to Formula I where substituent groups R1, R2, R3, R4, R5, R6, B and P are defined as set forth in the specification. The invention also provides methodology for synthesizing compounds according to Formula I and methodology for synthesizing PNA oligomers that incorporate one or more Formula I monomers.

Abstract: Compounds useful as nutritional supplements, antioxidants, heavy metal chelators and/or as intermediates for producing other related compounds with like uses have a formula: where R1 is an aromatic backbone and R2 is a sulfur containing ligand.

Abstract: A process for extraction of a peptide from a reaction mixture resulting from a peptide coupling reaction, the reaction mixture containing the peptide and a polar aprotic solvent selected from N,N-dimethylformamide, N,N-dimethylacetamide and N-methyl-2-pyrrolidone, whereby the process includes a step a) and a step b): step a) including the addition of a component a1), a component a2) and a component a3), whereby component a1) is an organic solvent 1, the organic solvent 1 is selected from 2-methyltetrahydrofuran and toluene, component a2) is water, and component a3) is an organic solvent 2, the organic solvent 2 is selected from the ethylacetate, isopropylacetate, acetonitrile, tetrahydrofuran and n-heptane to the reaction mixture, so that a biphasic system with an organic layer and an aqueous layer is obtained; step b) including the subsequent separation of the organic layer containing the peptide from the aqueous layer.

Abstract: An object is to provide a method for producing an ever-larger molecular weight collagen-like polypeptide single strand. Another object is to provide a method for controlling a molecular weight of a product to be obtained in desired magnitude upon producing a collagen-like polypeptide single strand. A solution is a method for producing a polypeptide including a step for allowing a condensation reaction of peptide oligomers represented by any one of formulas (1) to (3) (SEQ ID No:1 to SEQ ID No:3), wherein the condensation reaction is carried out in an aqueous solvent containing a phosphate ion in the range of 0 M to less than 0.01 M in the presence of a condensing agent, or a condensing agent and a condensing auxiliary: H-(Pro-Y-Gly)n-OH??(1); H-(Y-Gly-Pro)n-OH??(2); and H-(Gly-Pro-Y)n-OH??(3); wherein, in formulas (1) to (3), Y is hydroxyproline or proline, and n is an integer from 1 to 10.

Abstract: Protein concentrates and protein isolates, in addition to processes for the production of protein concentrates hydrolyzates thereof and protein isolates, are disclosed. In particular, the disclosure relates to a process for removing fiber from an oilseed meal, comprising: i) mixing an oilseed meal with a blending solvent, optionally water, saline solution, polysaccharide solution or protein containing solution, to form a mixture; ii) optionally adjusting the pH of the protein slurry to a pH of about 2 to about 10; iii) separating the mixture to form a protein slurry comprising soluble and insoluble proteins and an insoluble fiber fraction, and iv) extracting the protein slurry with an alcohol containing solvent to render soluble protein insoluble and separating and recovering the insoluble protein.

Abstract: The invention concerns methods and means for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.

Abstract: An anti-IL-23 antibody, including isolated nucleic acids that encode at least one anti-IL-23 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Abstract: Provided is a method for purification of TNFR:Fc fusion protein comprising hydrophobic interaction chromatography, wherein the buffer solution used in the said chromatography does not contain any additives.

Abstract: The invention relates to a process for the selective concentration of immunoglobulins or other proteins that contain an Fc domain (target protein), comprising the following steps: a. preparing a solution that contains the target protein; b. incorporating an Fc-binding protein with precisely two binding sites under conditions that allow binding to occur; c. separating the precipitate from the liquid phase; d. undoing the binding of the target protein from the Fc-binding protein.

Abstract: Described is the specific delivery of agrochemicals to plants. More specifically, a targeting agent has at least one binding domain that specifically binds to a binding site on an intact living plant. Such binding domains include a peptide having 4 framework regions and 3 complementary determining regions, or fragment(s) thereof, wherein the binding domains bind or retain a carrier onto a plant. Described are binding domains that specifically bind trichomes, stomata, cuticle, lenticels, thorns, spines, root hairs, or wax layer. Further described are methods for delivering agrochemicals to a plant, for depositing agrochemicals on a plant, and for retaining the agrochemicals on a plant, using targeting agents comprising the binding domains, and to methods for protecting a plant against stress or controlling plant growth. Also, described are methods for manufacturing a specifically targeting agrochemical carrier.

Abstract: The present invention relates to antibody-drug conjugate compounds of Formula I: Ab-(L-D)p??I where one or more maytansinoid drug moieties (D) are covalently linked by L to an antibody (Ab) which binds to an ErbB receptor, or which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be used in methods of diagnosis or treatment of cancer, and other diseases and disorders.

Abstract: Provided are crystalline ?, ?-disubstituted amino acids and their crystalline salts containing a terminal alkene on one of their side chains, as well as optionally crystalline halogenated and deuterated analogs of the ?, ?-disubstituted amino acids and their salts; methods of making these, and methods of using these.

Abstract: The present invention provides a continuous preparation method of ginseng ginsenosides and polysaccharides, whereby the ginseng extract liquor and supercritical solvent are poured continuously into a separation tank at 10-30 MPa and 40-60° C. as well as a preset flow rate; so the ginseng extract liquor can be separated in the separation tank to obtain ginseng ginsenosides and polysaccharides at different positions of the separation tank.

Abstract: Disclosed is an anti-infective drug-macrolide derivate, preparation and uses thereof. Macrolide derivate, namely erythromycin ethylsuccinate crystalline hydrate, which has less moisture absorption and good storage stability, can be used in the preparation of medicaments for the treatment and prevention of human or animal infectious diseases caused by Gram-positive or negative bacteria.

Abstract: We describe anhydride compounds suitable for physiologically labile modification of amine-containing molecules. The described anhydrides form reversible linkages having desirable kinetics for in vivo delivery of biologically active molecules. Also described are endosomolytic polymers formed by modification of membrane active polyamines with the described anhydrides.

Abstract: A fructose absorption inhibitor according to the present invention comprises a hydrolyzable tannin as an active ingredient. The hydrolyzable tannin preferably has a form composed of a gallic acid derivative and/or an ellagic acid derivative bound to a hydroxy group in glucose via an ester bond, and includes ellagitannin, gallotannin and so on.

Abstract: A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.

Abstract: The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.

Abstract: A method for treating and/or diagnosing pain and the source or type of pain, shock, and/or inflammatory conditions in a subject. A method of using a therapeutically effective amount of a DNA or RNA aptamer that shows high affinity for OLAMs to at least partially treat pain, shock, and/or inflammatory conditions in a subject. The DNA or RNA aptamer that shows high affinity for OLAMs may be coupled to a plasma protein binding compound or a pharmacologically active agent. A method of treating and or diagnosing pain, shock, and/or inflammatory conditions in a subject may include inactivating or preventing at least one linoleic acid metabolite to treat certain conditions (e.g., pain, shock, and/or inflammation) using a DNA or RNA aptamer that shows high affinity for OLAMs.

Abstract: The present invention provides a novel technique by which the redox activity of a nucleic acid molecule can be evaluated. An evaluation method of the present invention includes: a detection step of electrochemically detecting a redox reaction to a substrate, the redox reaction being catalyzed by a nucleic acid molecule to be evaluated, using a device that electrochemically detects a redox reaction; and an evaluation step of evaluating redox activity of the nucleic acid molecule from a result of the detection of the redox reaction. As the device, a device in which a base provided with a detection portion is included, the detection portion. includes an electrode system, and the nucleic acid molecule to be evaluated is arranged on the base is used. In the present invention, it is preferred that a plurality of kinds of nucleic acid molecule to be evaluated is arranged on the base, and the plurality of kinds of nucleic acid molecules to be evaluated is evaluated by a single device.

Abstract: The invention provides hydrolases, polynucleotides encoding them, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention is directed to polypeptides, e.g., enzymes, having a hydrolase activity, e.g., an esterase, acylase, lipase, phospholipase (e.g., phospholipase A, B, C and D activity, patatin activity, lipid acyl hydrolase (LAH) activity) or protease activity, including thermostable and thermotolerant hydrolase activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The hydrolase activities of the polypeptides and peptides of the invention include esterase activity, lipase activity (hydrolysis of lipids), acidolysis reactions (to replace an esterified fatty acid with a free fatty acid), transesterification reactions (exchange of fatty acids between triglycerides), ester synthesis, ester interchange reactions, phospholipase activity and protease activity (hydrolysis of peptide bonds).

Abstract: A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.

Abstract: The invention relates to a method for inducing or promoting skipping of exon 45 of DMD pre-mRNA in a Duchenne Muscular Dystrophy patient, preferably in an isolated (muscle) cell, the method comprising providing an isolate muscle cell with a molecule that binds to a continuous stretch of at least 21 nucleotides within said exon. The invention further relates to such molecule used in the method.

Abstract: Provided herein are processes for the preparation of 5-azacytidine, useful for treating, preventing, and/or managing diseases or conditions including cancer, disorders related to abnormal cell proliferation, hematologic disorders, and myelodysplastic syndromes (MDS), wherein 5-azacytidine is represented by the structure:

Abstract: A method for manufacturing a modified hydroxyethyl starch carrying a heptonic acid residue on at least one of its termini is disclosed. Within this method, the following steps are carried out: a) dissolving hydroxyethyl starch in water, b) adjusting the pH value to a value of 8.0 to 10.0, c) adding a cyanide compound to the hydroxyethyl starch solution, heating the solution to a temperature of 80 to 99° C. and keeping it at this temperature for a first time period, and d) adjusting the pH value to a value of 2.0 to 4.0, bringing the solution to a temperature of 50 to 90° C. and keeping it at this temperature for a second time period.

Abstract: The present invention provides processes for stereoselectively preparing C-arylglucosides that can be useful as synthetic building block or drugs, including SGLT2 inhibitors.

Abstract: This invention relates to a detection system for measuring a fluorescent signal in a fluorescent assay. The system comprises a probe having a small sensing surface bound with a fluorescent label, and a light source and a detector both mounted at the proximal side of the sensing surface of the substrate. The invention also relates to a method for detecting an analyte in a liquid sample using a probe tip having a small surface area (?5 mm) and a high molecular weight polymer (?1 MD) having multiple binding molecules and multiple fluorescent labels. The binding reaction is accelerated by flowing the reaction solutions laterally and moving the probe tip up and down in the reaction vessels. The invention furthers relates to a fluorescent labeling composition comprising a cross-linked FICOLL® molecule having a plurality of binding molecules and a plurality of fluorescent labels.

Abstract: The present invention provides: a polysaccharide derivative containing a structure wherein hydrogen atoms in a hydroxyl group at the 2-position and the 3-position of a structure unit of polysaccharide are substituted with different substituents respectively represented by a specific general formula; and, a separating agent for optical isomers, which contains such a polysaccharide derivative. The present invention can provide a novel polysaccharide derivative which has excellent optical isomer separating ability, and is thus suitable for a separating agent for optical isomers, and can provide a separating agent for optical isomers which contains the polysaccharide derivative.

Abstract: Process for the synthesis of the compound of formula (I): Application in the synthesis of ivabradine, addition salts thereof with a pharmaceutically acceptable acid and hydrates thereof.

Abstract: The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating certain protein kinases such as mTor, tyrosine kinases, and/or lipid kinases such as PI3 kinase. Also provided in the present invention are methods of using these compositions to modulate activities of one or more of these kinases, especially for therapeutic applications.

Abstract: The present invention provides methods of synthesizing compounds of formula (1) and intermediates thereto. The present invention also provides intermediates useful in the synthesis of compounds of formula (1).

Abstract: This invention relates to a procedure for obtaining a thiophene-2-carboxamide compound, specifically rivaroxaban, which comprises the (i) fragmentation of the N?C bond of a compound of formula 23 where R1 is selected among hydrogen, halogen, and (C1-C6)alkyl; and (ii) acylation of the resulting intermediate with 5-chloro-tiofen-2-carbonyl chloride in a solvent medium, in the presence of a base. The invention also relates to the compounds of formula 23 and their use in the obtention of rivaroxaban.

Abstract: Methods for isolating 9-{(R)-2-[((S)—{[(S)-1-(isopropoxycarbonyl)ethyl]amino}phenoxyphosphinyl)methoxy]propyl}adenine (compound 16): a method for preparing, in high diastereomeric purity, intermediate compounds 13 and 15: and a method for preparing intermediate compound 12: 9-{(R)-2-[((S)—{[(S)-1-(isopropoxycarbonyl)ethyl]amino}phenoxyphosphinyl)methoxy]propyl}adenine has anti-viral properties.

Abstract: The invention described herein relates to novel fused pyrimidinediones derivatives of formula (I) which are TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). This invention also provides processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.

Abstract: The present invention relates to substituted xanthines of general formula wherein R1 to R3 are as defined herein, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Abstract: A crystal of (S,E)-2-(2,6-dichlorobenzamido)-5-[4-(methyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid has excellent chemical and physical stability, and a medical use thereof.

Abstract: An antipruritic which exerts an antipruritic effect based on a novel action mechanism and is effective for pruritus. The antipruritic contains as an effective ingredient a compound which activates a central type nicotinic acetylcholine receptor.

Abstract: There is provided salts and polymorphs of sitagliptin, processes for the preparation thereof, and pharmaceutical compositions comprising the same.

Abstract: A process for preparing photoresponsive hybrid organic-inorganic particles comprises (a) combining (1) at least one organosilane compound comprising at least two silicon-bonded groups selected from hydroxyl groups, hydrolyzable groups, and combinations thereof and (2) at least one neat photoactive material, to form a ceramic precursor composition; and (b) allowing or inducing hydrolysis of the hydrolyzable groups and condensation of the organosilane compound to form hybrid organic-inorganic particles comprising the photoactive material.

Abstract: An object of the present invention is to provide a novel pyrroloquinoline quinone disodium crystal having excellent dispersibility in solvents and excellent permeability through skin, and a method for producing the pyrroloquinoline quinone disodium crystal with high efficiency. According to the present invention, provided are a novel pyrroloquinoline quinone disodium crystal which is produced by drying a crystal produced under specified conditions through a drying means such as lyophilization, ambient drying and vacuum drying, and a method for producing the pyrroloquinoline quinone disodium crystal.

Abstract: Disclosed herein are R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and L-aspartic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same for antimicrobial. Because the R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and L-aspartic acid salt is more soluble and less toxic and has less side effects as an antimicrobial agent than hydrochloride and the other salts (D-aspartate and phosphate) conventionally used, the salt may be useful for oral and injectable administration.

Abstract: In order to produce an intermediate from which a cyclic alcohol compound can be stereoselectively obtained, a method for producing an oxetane compound according to the present invention includes the step of reacting, with a cyanide salt, a compound represented by Formula (I): wherein R1 is selected from a hydrogen atom and an alkyl group optionally having a substituent; X1 is selected from a halogen atom and —OSO2R3 where R3 is selected from an alkyl group optionally having a substituent, a phenyl group, and a naphthyl group; and a ring Z1 represents a cyclic hydrocarbon optionally having a substituent, to obtain a compound represented by Formula (II):